Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekten af ​​fodtøjsgenereret biomekanisk manipulation på symptomer på stressurininkontinens (SUI)

19. august 2026 opdateret af: Montefiore Medical Center
FGBMM (fodtøjsgenereret biomekanisk manipulation) påvirker neuromuskulære mønstre af bækkenmuskler. Selvom der ikke har været offentliggjorte undersøgelser efter vores viden, der undersøger effekten af ​​FGBMM på urininkontinens, forårsager FGBMM forstyrrelser i balance og gang, der skaber dynamik svarende til dynamiske lumbosakrale stabiliseringsøvelser. Efterforskerne foreslår, at FGBMM inducerer de samme biomekaniske forbedringer som LPSE (lumbopelvic stabiliseringsøvelser), som har vist fordele for inkontinens. I stedet for at instruere patienterne i at sammentrække den nedre krop og bækkenbundsmusklerne, som det almindeligvis gøres for LPSE, kan de sko, der bruges i FGBMM, kalibreres på en måde, der får denne sammentrækning til at forekomme, uden at patienten opdager det. Fordelagtig bækken- og rygsøjlepositionering kan også opnås ved strategisk placering af bælgerne uden at skulle instruere patienten i komplicerede manøvrer. Ved at udnytte den fremragende overholdelse og kliniske fordele ved FGBMM på relaterede tilstande, foreslår efterforskerne at evaluere virkningerne af FGBMM ud over bækkenbundsterapi for at forbedre symptomerne på stress-urininkontinens i en bybefolkning i en indre by.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

FGBMM (fodtøjsgenereret biomekanisk manipulation) påvirker neuromuskulære mønstre af bækkenmuskler. Selvom der ikke har været offentliggjorte undersøgelser efter vores viden, der undersøger effekten af ​​FGBMM på urininkontinens, har FGBMM vist sig at forårsage forstyrrelser i balance og gang, der skaber dynamik svarende til dynamiske lumbosakrale stabiliseringsøvelser. Til støtte for denne teori, selvom den ikke er offentliggjort, har en af ​​grundlæggerne af teknikken, Avi Elbaz, bemærket anekdotisk bevis for, at patienter, der havde SUI (stress urininkontinens) og gennemgik FGBMM for knæ- eller lænderygsmerter, rapporterede forbedring af inkontinens. Efterforskerne foreslår, at FGBMM inducerer de samme biomekaniske forbedringer som LPSE (lumbopelvic stabiliseringsøvelser), som har vist fordele for inkontinens. Bælgerne på fodtøjet kan placeres for at udfordre patientens balance på en måde, der svarer til den måde, hvorpå trampoliner bruges i LPSE. I stedet for at instruere patienterne i at sammentrække den nedre krop og bækkenbundsmusklerne, som det almindeligvis gøres for LPSE, kan de sko, der bruges i FGBMM, kalibreres på en måde, der får denne sammentrækning til at forekomme, uden at patienten opdager det. Fordelagtig bækken- og rygsøjlepositionering kan også opnås ved strategisk placering af bælgerne uden at skulle instruere patienten i komplicerede manøvrer. En yderligere fordel ved FGBMM er, at denne øvelse udføres med øget intraabdominalt tryk, der efterligner tilstanden og indstillingen, når inkontinens opstår, snarere end statisk træning, der bruges i PFT. Mens de udfører regelmæssige aktiviteter, sidder folk naturligt på hug og laver andre aktiviteter, der øger det intra-abdominale tryk. Ydermere er FGBMM mere praktisk for folk med travle tidsplaner, fordi det kan opnås med et meget mindre tidsforbrug fra patienten end traditionel PFT, da det udføres under normal aktivitet. Ved at udnytte den fremragende overholdelse og kliniske fordele ved FGBMM på relaterede tilstande, foreslår efterforskerne at evaluere virkningerne af FGBMM ud over bækkenbundsterapi for at forbedre symptomerne på stress-urininkontinens i en bybefolkning i en indre by.

En potentiel brug af FGBMM ved at bruge sko som et supplement til traditionel bækkenbundsterapi kan give en mere effektiv terapi med bedre vedhæftning. Problemer med traditionel terapi omfatter dårlig patientadhærens (patienter gennemfører ofte ikke sessionerne og har dårlig adhærens (ca. 50%), manglende fortsættelse i et igangværende program, hvilket fører til tilbagefald og behov for genbehandling eller endda ringe klinisk fordel. Derudover er adgangen til bækkenbundsbehandling begrænset for mange patienter, da der ikke er nok tilgængelige ambulante behandlingstilbud til at imødekomme alle patienters behov. At finde et ekstra træningsprogram, der vil øge overholdelse og forbedre patientresultater med bedre kliniske fordele, er en høj prioritet fra både patientpleje og omkostningsstyringsperspektiver.

FGBMM-brug af sko overvinder potentielt mange af disse problemer med at forbedre/modificere unormal biomekanik af bækkenbundsmuskler (derfor mindske inkontinens), og et hjemmebaseret træningsprogram, der bruger fodtøj, der forårsager træning med normal aktivitet ved at fremme forstyrrelser. Denne biomekaniske tilgang kan væsentligt forbedre symptomerne på urininkontinens hos patienter med Stress SUI eller Blandet urininkontinens. Ud fra den rapporterede fremragende overholdelse og kliniske fordele ved FGBMM hos patienter med beslægtede tilstande foreslår efterforskerne at evaluere den biomekaniske øvelse (at bære en passende kalibreret sko derhjemme i et foreskrevet tidsrum hver dag) som en konservativ behandling, der kan supplere traditionel bækkenbundsterapi, medicin og endda kirurgisk indgreb for det samme i en indre bybefolkning.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

64

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New York
      • The Bronx, New York, Forenede Stater, 10461
        • Montefiore Medical Center - Medical Park Campuses

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Beskrivelse

Inklusionskriterier:

  • Stress eller blandet urininkontinens, baseret på UDI-6.
  • Kvinder mellem 18-75 år.
  • Vægt mindre end 350 lbs.
  • Ambulante og aktive patienter, der kan deltage i et genoptræningsprogram, der inkluderer daglig gang
  • Kunne gå mindst 50 meter og scorede positivt på STEADI-testen
  • Kunne forstå, læse og underskrive den informerede samtykkeerklæring
  • engelsk eller spansktalende

Ekskluderingskriterier:

  • Forudgående operation for inkontinens
  • Bækkenbundsterapi inden for de seneste 6 måneder.
  • I øjeblikket gravid
  • Overvejende urge-inkontinens.
  • Patienter med mere end 3 fald inden for de sidste 52 uger, ELLER ethvert balancerelateret fald med en skade inden for de sidste 52 uger.
  • Patienter, der udviser manglende fysisk eller mental evne til at udføre eller overholde undersøgelsesproceduren.
  • Patienter med en anamnese med patologisk osteoporotisk fraktur
  • Enhver større hjerte-kar-komorbiditet, der forbyder tilmelding til et aktivt træningsprogram
  • Aktiv hjertesygdom (indlæggelser af iskæmi eller hjertesvigt inden for 24 uger) og aktiv KOL (forværring inden for 24 uger)
  • Aktive maligniteter ved igangværende behandling
  • Patient med neurologisk gangmønster.
  • Patient, der har brug for hjælpemiddel under ganganalyse.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Aktiv komparator: Traditional Pelvic Floor Physical Therapy (PFPT)
Up to six sessions, with one session every alternate week.
Participant will receive six sessions of PFPT, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
Eksperimentel: FGBMM plus Traditional Pelvic Floor Physical Therapy (PFPT)
Treatment with FGBMM using shoes with pertupods daily at home along with traditional pelvic floor therapy sessions.
Participants will have FGBMM using shoes with pertupods along with traditional PFPT over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Severity of Stress Urinary Incontinence (SUI) Symptoms
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Severity of SUI symptoms was measured using the six-item Urogenital Distress Inventory (UDI-6). The UDI-6 is a validated, patient-reported questionnaire which assesses the severity of symptoms of urinary incontinence. It includes questions evaluating the frequency of urination, incontinence/leakage, difficulty with complete bladder emptying, and pain. Responses on the UDI-6 are rated on a 5-point scale ranging from 0 ("No/Not present") to 4 ("Quite a bit"). Raw scores were summed, averaged, and multiplied by 25 to yield a final score scale ranging from 0-100. Higher scores are indicative of greater distress due to symptom severity. Results are summarized by study arm.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life as Determined by the Urinary Impact Questionnaire (UIQ-7)
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Quality of Life will be determined with the use of the UIQ-7 subscale component of the Pelvic Floor Impact Questionnaire-short form 7 (PFIQ-7) questionnaire. Specifically, the UIQ-7 questions within the PFIQ-7 are used to assess the impact of bladder or urine symptoms or conditions on a participant's daily function and activities, social health, or mental health over the prior 3 months. Participants provide responses for each question on 4-point scale ranging from 0 ("Not at all") to 3 ("Quite a bit"). Mean scores are averaged and multiplied by 100/3 to yield an overall possible score of 0-100, such that higher scores are indicative of a greater negative impact on quality of life from pelvic floor dysfunction. Scores are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Pelvic Floor Muscle (PFM) Activity - Average Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFM average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average contraction results values are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Pelvic Floor Muscle (PFM) Activity - Maximum Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Maximum contraction results values are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Pelvic Floor Muscle (PFM) Activity - Average Rest
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average rest results values are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Pelvic Floor Muscle (PFM) Activity - Change From Average Contraction to Average Rest
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Change From Average Contraction to Average Rest results values are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Pelvic Floor Muscle (PFM) Activity - Average Abdominal Contraction
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
PFM Activity was assessed during each visit by surface electromyography (sEMG). sEMG recording of the pelvic floor muscle activity was conducted via the use of Prometheus CTS 2000 EMG machine and vaginal sensor for optimal recording and was performed after pelvic examinations had been done to ensure there were no contraindications for the use of the probe. Neuromuscular electrical stimulation with 50 HZ was done via the use of the same intra-vaginal probe for the enhancement of the pelvic floor muscles. Electrical signals (microvolts) were measured during specific tasks and PFV average contraction, maximum contraction, and average rest results were calculated and reported in microvolts. Increased amplitude in waveforms, and corresponding result values, were associated with stronger muscle activation and decreased urinary incontinence. Average Abdominal Contraction results values are summarized by study arm using basic descriptive statistics.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Adherence to Treatment
Tidsramme: Baseline to 24 weeks (~Six months)
Adherence to FGBMM and PFPT was assessed based on self-reporting of in-person PFPT visits and in-person calibration visits (Dual Therapy study arm only) on an end of study questionnaire. Median number of visits is calculated and summarized by study arm.
Baseline to 24 weeks (~Six months)

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Total Healthcare Costs
Tidsramme: Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Total costs associated with PFPT or PFPT+FGBMM will be summarized. Costs will include those associated with physical therapy, emergency department (ED) visits, medications, imaging studies, surgical procedures, physician visits related to symptoms of incontinence, and total physician visits. Mean costs will be summarized by study arm.
Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks (~Six months)
Gait Assessment
Tidsramme: Six months
The gait assessment consists of the Spatio-temporal gait assessment including the following parameters: gait velocity, cadence, step length, gait cycle phases, step width, toe-in/out angle, center of pressure trajectory single limb support and limb symmetry measured by gait analysis. Results will be summarized by study arm.
Six months
Change in Total Healthcare Utilization
Tidsramme: 6 months
Change in total healthcare facility utilization, including physical therapy, ED visits, pharmacological treatments, imaging studies, surgical procedures, physician visits related to symptoms of incontinence and total physician visits, as assessed by patient interview.
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Anna M Lasak, MD, Montefiore Medical Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. november 2017

Primær færdiggørelse (Faktiske)

12. december 2023

Studieafslutning (Faktiske)

12. december 2023

Datoer for studieregistrering

Først indsendt

19. juni 2017

Først indsendt, der opfyldte QC-kriterier

20. juni 2017

Først opslået (Faktiske)

21. juni 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

19. august 2026

Sidst verificeret

1. august 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2016-7163

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Ubesluttet med at dele dataene.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ja

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .